1-bromo-4-[(dimethylphosphoryl)methyl]benzene | 119199-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-bromo-4-[(dimethylphosphoryl)methyl]benzene
• 英文别名: 1-Bromo-4-(dimethylphosphorylmethyl)benzene
• CAS: 119199-90-5
• 化学式: C₉H₁₂BrOP
• 分子量: 247.071
• InChiKey: FGJPFDJNTTYULW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-bromo-4-[(dimethylphosphoryl)methyl]benzene 、 (1R,11R)-18-(difluoromethoxy)-12-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,9,12-triazapentacyclo[9.8.1.0^{2,10}.0^{3,8}.0^{14,19}]icosa-3(8),4,6,9,14(19),15,17-heptaen-13-one 在 potassium phosphate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以59 %的产率得到(1R,11R)-18-(difluoromethoxy)-5-{4-[(dimethylphosphoryl)methyl]phenyl}-12-methyl-2,9,12-triazapentacyclo[9.8.1.0^{2,10}.0^{3,8}.0^{14,19}]icosa-3(8),4,6,9,14(19),15,17-heptaen-13-one
  参考文献：
  名称：

  MODULATORS OF TNF-α ACTIVITY

  摘要：

  Provided herein are inhibitors of TNFα, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNFα inhibitory compounds for the treatment of diseases or disorders.

  公开号：

  WO2024112796A1
• 作为产物：
  描述：

  对溴溴苄 、 二甲基氧化膦 在 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 以48 %的产率得到1-bromo-4-[(dimethylphosphoryl)methyl]benzene
  参考文献：
  名称：

  MODULATORS OF TNF-α ACTIVITY

  摘要：

  Provided herein are inhibitors of TNFα, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNFα inhibitory compounds for the treatment of diseases or disorders.

  公开号：

  WO2024112796A1

文献信息

• AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING THE SAME
  申请人：Mizuki Yumiko

  公开号：US20110233534A1

  公开（公告）日：2011-09-29

  An aromatic amine derivative represented by the following formula (1); wherein Ar 1 to Ar 4 are independently a substituted or unsubstituted aryl group having 6 to 20 ring carbon atoms or a substituted or unsubstituted heteroaryl group having 5 to 20 ring carbon atoms and at least one of Ar 1 to Ar 4 has a substituted or unsubstituted silyl group; Ar 5 is a substituted or unsubstituted arylene group having 6 to 20 ring carbon atoms or a substituted or unsubstituted heteroarylene group having 5 to 20 ring carbon atoms; and L is a group represented by the following formula (A) or (B);
• AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME
  申请人：Mizuki Yumiko

  公开号：US20130221331A1

  公开（公告）日：2013-08-29

  A compound is shown by the following formula (1). wherein l, m, and n are independently an integer from 1 to 3, Ar 1 to Ar 4 are independently a substituted or unsubstituted aryl group having 6 to 30 ring carbon atoms, or a substituted or unsubstituted heteroaryl group having 5 to 30 ring atoms, Ar 5 , Ar 6 , and Ar 7 are independently a substituted or unsubstituted arylene group having 6 to 30 ring carbon atoms, or a substituted or unsubstituted heteroarylene group having 5 to 30 ring atoms, and p is an integer from 0 to 2, and Ar 6 and N are bonded via a single bond when p is 0, provided that at least one of Ar 1 to Ar 4 is substituted with a substituted silyl group, a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms, or a substituted or unsubstituted cycloalkyl group having 3 to 10 carbon atoms, and at least one of Ar 1 to Ar 4 is substituted with a cyano group.
• [EN] APOL1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS D'APOL1 ET MÉTHODES D'UTILISATION
  申请人：[en]MAZE THERAPEUTICS, INC.

  公开号：WO2023141432A2

  公开（公告）日：2023-07-27

  Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, whereinm, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1 -mediated disease, disorder, or condition in an individual.